Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Ava Ferguson Bryan, MD, AM, Elizabeth Yates, MD, MPH, and Neelima Tummala, MD, MSc
The health sector has obligations and ample opportunities to protect health by decreasing waste and motivating more system-wide sustainable clinical practices.
AMA J Ethics. 2022;24(10):E927-933. doi:
10.1001/amajethics.2022.927.